respiratori
tract
infect
one
common
caus
diseas
human
absente
healthcar
canada
influenzalik
ill
consult
rate
rang
per
patient
influenza
season
ill
caus
primari
tool
prevent
influenza
annual
vaccin
osterholm
et
report
efficaci
trival
inactiv
influenza
vaccin
eight
random
control
trial
adult
year
age
neuraminidas
inhibitor
may
also
effect
prevent
influenza
estim
efficaci
placebocontrol
healthcar
worker
provid
direct
patient
care
may
increas
risk
develop
influenza
compar
healthi
may
transmit
diseas
vulner
patient
make
prioriti
group
influenza
vaccin
event
pandem
antivir
influenza
season
pilot
studi
determin
adher
antivir
medic
influenza
season
rel
efficaci
antivir
prophylaxi
zanamivir
season
influenza
vaccin
laboratoryconfirm
influenza
infect
determin
risk
factor
acut
respiratori
ill
ari
among
healthi
adult
recruit
occur
novemb
novemb
mount
sinai
hospit
acut
care
bed
academ
health
centr
toronto
canada
particip
elig
year
old
avail
followup
studi
period
provid
written
inform
consent
individu
exclud
health
medic
condit
contraind
influenza
vaccin
zanamivir
administr
receiv
influenza
vaccin
prior
studi
start
date
pregnant
plan
pregnant
breastfeed
receiv
immunoglobulin
therapi
within
month
studi
entri
particip
studi
investig
drug
studi
period
immunocompromis
condit
therapi
women
childbear
potenti
prophylaxi
arm
requir
neg
pregnanc
test
prior
receiv
prescript
zanamivir
nonblind
random
control
pilot
studi
particip
random
two
one
ratio
antivir
prophylaxi
influenza
vaccin
random
number
tabl
use
gener
assign
block
staff
member
affili
studi
gener
list
provid
assign
studi
nurs
follow
consent
particip
vaccin
group
receiv
one
intramuscular
inject
glaxosmithklin
mississauga
canada
trival
inactiv
split
virion
influenza
vaccin
contain
influenza
particip
antivir
prophylaxi
arm
prescrib
one
mg
dose
zanamivir
glaxosmithklin
per
day
influenza
season
particip
experienc
side
effect
discontinu
antivir
prophylaxi
given
either
sanofi
pasteur
toronto
canada
remain
antivir
arm
studi
analysi
influenza
season
defin
priori
start
proport
specimen
test
influenza
provinc
posit
week
two
consecut
week
end
proport
less
posit
two
consecut
week
definit
establish
keep
risk
exposur
influenza
low
particip
prophylact
antivir
medic
studi
approv
health
canada
mount
sinai
hospit
research
ethic
board
regist
clinicaltrialsgov
conduct
accord
good
clinic
practic
guidelin
data
collect
start
day
enrol
continu
end
season
influenza
season
demograph
risk
factor
health
statu
inform
collect
questionnair
enrol
facetofac
interview
weekli
webbas
diari
daili
ill
questionnair
ari
shown
blood
sampl
collect
four
time
baselin
prior
vaccin
vaccin
group
day
vaccin
vaccin
group
start
influenza
season
antivir
prophylaxi
group
day
influenza
season
midseason
week
end
influenza
season
sera
extract
store
frozen
later
test
activ
surveil
acut
respiratori
ill
occur
use
webbas
weekli
diari
symptom
throughout
influenza
season
particip
acut
respiratori
symptom
runni
stuffi
nose
sneez
sore
scratchi
throat
hoars
cough
unexplain
fever
ask
nasopharyng
np
swab
collect
studi
nurs
selfcollect
midturbin
nasal
adher
prophylaxi
assess
use
weekli
diari
medic
count
four
studi
visit
midturbin
nasal
np
swab
sampl
test
influenza
viru
use
cdc
influenza
matrix
influenza
b
naat
ontario
public
health
laboratori
toronto
unus
media
frozen
test
use
ace
seegen
seoul
korea
multiplex
naat
respiratori
virus
metapneumoviru
adenoviru
abcd
human
coronaviru
parainfluenza
viru
influenza
b
respiratori
synctial
viru
b
rhinoviru
ab
end
season
hemagglutin
inhibit
hai
assay
use
measur
antibodi
specif
influenza
yamagata
victoria
serum
sampl
particip
hai
perform
dalhousi
univers
halifax
nova
scotia
use
turkey
erythrocyt
hemagglutinin
unit
per
viru
base
whorecommend
laboratori
technician
blind
arm
particip
assign
laboratoryconfirm
influenza
infect
defin
symptomat
infect
confirm
naat
test
either
np
midturbin
nasal
swab
seroconvers
vaccin
defin
postvaccin
titr
prevaccin
titr
fourfold
greater
increas
hai
acut
respiratori
ill
defin
recent
onset
least
two
symptom
least
one
respiratori
among
rhinorrheanas
congest
sore
throat
cough
headach
particip
remain
arm
random
modifi
intentiontotreat
analys
peopl
withdrew
prior
influenza
season
condit
logist
regress
match
week
ill
onset
use
account
timevari
risk
factor
exposur
ill
famili
patient
robust
varianc
estim
use
adjust
correl
due
sever
ari
report
particip
weekli
report
peopl
without
sign
symptom
respiratori
ill
use
control
week
without
report
ill
elig
inclus
analys
assumpt
logist
regress
model
check
use
scatter
plot
residu
predictor
statist
analys
perform
use
statacorp
colleg
station
tx
usa
p
valu
consid
statist
signific
test
twosid
sensit
analysi
condit
logist
regress
model
conduct
peopl
discontinu
antivir
prophylaxi
reclassifi
vaccin
arm
postvaccin
neglig
differ
covari
regress
coeffici
estim
detect
result
present
particip
recruit
studi
random
antivir
arm
vaccin
arm
shown
baselin
characterist
similar
two
group
median
age
particip
year
femal
chronic
diseas
three
individu
work
health
care
facil
provid
direct
patient
care
two
individu
vaccin
group
two
prophylaxi
group
withdrew
studi
prior
start
influenza
season
exclud
analys
influenza
season
start
week
decemb
studi
continu
may
week
pandem
strain
start
circul
ontario
week
april
first
wave
peak
week
may
june
particip
prophylaxi
group
start
take
medic
januari
start
first
week
start
second
week
januari
three
individu
discontinu
prophylaxi
due
side
effect
one
week
nausea
vomit
headach
two
peopl
week
one
joint
pain
one
increas
nasal
congest
three
vaccin
upon
discontinu
week
april
expect
durat
season
studi
particip
antivir
group
given
option
discontinu
prophylaxi
vaccin
n
vaccin
april
restart
prophylaxi
april
due
increas
local
pandem
influenza
activ
discontinu
prophylaxi
without
vaccin
n
continu
prophylaxi
addit
weeksth
next
plan
studi
visit
n
continu
addit
weeksend
studi
n
medic
taken
median
day
rang
good
adher
accord
selfreport
weekli
diari
particip
took
prescrib
dose
use
prophylaxi
adher
higher
start
prophylaxi
averag
dose
taken
per
week
march
drop
march
may
see
baselin
level
seroprotect
strain
includ
season
influenza
vaccin
similar
two
group
shown
vaccin
met
usa
center
biolog
evalu
research
guidelin
criteria
seroprotect
seroconvers
met
neither
criterion
season
vaccin
produc
canada
antigen
strain
use
place
whorecommend
thu
seroconvert
follow
vaccin
particip
seroconvert
strain
circul
four
case
per
personseason
influenza
infect
detect
three
case
symptomat
detect
naat
fourth
detect
serolog
alon
two
case
occur
particip
vaccin
arm
test
posit
influenza
season
strain
neither
signific
increas
hai
titr
test
strain
one
particip
random
antivir
prophylaxi
report
take
prescrib
dose
test
posit
influenza
b
naat
februari
chang
hai
titr
second
person
take
antivir
prophylaxi
report
symptom
acut
respiratori
ill
questionnair
question
final
studi
visit
increas
antibodi
titr
individu
report
complianc
prophylaxi
stop
take
medic
may
final
studi
visit
blood
draw
juli
period
discontinu
medic
blood
draw
peak
first
wave
pandem
make
possibl
particip
expos
discontinu
zanamivir
prophylaxi
case
use
analys
effect
shown
episod
acut
respiratori
ill
report
particip
episod
per
particip
differ
number
episod
peopl
receiv
prophylact
antivir
medic
compar
receiv
season
influenza
vaccin
rr
p
follow
adjust
week
ill
shown
result
unadjust
condit
logist
regress
analysi
match
week
ill
determin
odd
report
ill
higher
older
particip
provid
direct
patient
care
odd
report
acut
respiratori
ill
also
increas
recent
exposur
past
day
patient
cowork
spous
child
symptom
respiratori
ill
use
multivari
model
adjust
impact
factor
odd
report
acut
respiratori
ill
doubl
follow
recent
exposur
patient
child
symptom
time
higher
follow
exposur
spous
symptom
acut
respiratori
ill
particip
random
control
studi
larg
abl
will
use
antivir
prophylaxi
influenza
entir
influenza
season
particip
take
least
schedul
dose
week
prophylaxi
studi
peopl
discontinu
antivir
medic
due
side
effect
similar
unblind
random
control
trial
adult
take
oseltamivir
given
influenza
vaccin
prevent
influenza
infect
studi
particip
discontinu
prophylaxi
due
side
effect
full
influenza
comparison
three
blind
random
placebocontrol
trial
particip
studi
arm
discontinu
zanamivir
oseltamivir
placebo
prophylaxi
due
side
effect
experienc
adult
season
influenza
vaccin
prevent
laboratoryconfirm
influenza
ill
compar
random
placebocontrol
studi
antivir
prophylaxi
protect
efficaci
zanamivir
oseltamivir
laboratoryconfirm
influenza
rang
adult
adolesc
studi
rang
durat
day
studi
directli
compar
vaccin
antivir
prophylaxi
includ
current
studi
anoth
pilot
studi
conduct
facil
highlight
fact
neither
option
perfect
provid
greater
protect
intervent
antivir
prophylaxi
may
provid
protect
higher
risk
contract
transmit
andor
suffer
sever
consequ
infect
caus
influenza
strain
includ
season
vaccin
eg
pandem
year
signific
mismatch
vaccin
circul
strain
studi
direct
provis
patient
care
exposur
patient
symptom
acut
respiratori
infect
previou
week
associ
higher
odd
ill
consist
studi
report
peopl
work
healthcar
institut
higher
risk
acut
respiratori
ill
peopl
work
william
et
report
peopl
work
acut
care
hospit
germani
higher
odd
report
ari
influenza
season
peopl
work
employ
adjust
age
sex
smoke
statu
current
studi
risk
acut
respiratori
ill
also
higher
particip
expos
spous
child
ill
previou
week
exposur
ill
famili
member
report
risk
factor
influenza
healthcar
worker
live
otherwis
expos
risk
respiratori
ill
sever
studi
limit
pilot
studi
inabl
blind
particip
treatment
may
bias
report
respiratori
symptom
side
effect
antivir
medic
secondli
particip
provid
exposur
inform
report
ari
like
bias
recal
exposur
peopl
symptom
acut
respiratori
ill
also
sinc
pandem
strain
influenza
start
circul
toward
end
plan
studi
period
like
increas
longterm
adher
prophylact
antivir
medic
previou
studi
found
adher
start
wane
toward
end
influenza
studi
particip
work
acut
care
facil
regular
internet
access
like
studi
popul
higher
socioeconom
statu
gener
popul
may
limit
generaliz
find
strength
studi
random
overwhelm
major
particip
consist
complet
weekli
diari
reduc
recal
bia
symptom
exposur
neuraminidas
inhibitor
effect
prevent
influenza
infect
adult
compli
schedul
daili
dose
full
season
low
percentag
discontinu
side
effect
exposur
spous
child
patient
symptom
acut
respiratori
ill
within
past
week
risk
factor
respiratori
ill
healthi
adult
exemplifi
need
follow
guidelin
prevent
spread
respiratori
infect
home
workplac
